Brentuximab vedotin

US-HEALTH-PEOPLE-RESEARCH-CANCER-pharmaceutical

Targeted Therapy for Children With High-risk Hodgkin's Lymphoma Reduced Relapse Rates

Medicine & Technology Nov 04, 2022

A large multicenter clinical trial showed that a combination of targeted therapy and chemotherapy reduced the likelihood of children relapsing from Hodgkin's lymphoma by 10%. Read the article to learn more details about the study.

Brentuximab vedotin

Targeted Therapy for Children With High-risk Hodgkin's Lymphoma Reduced Relapse Rates

Most Popular

Cave of Death in Costa Rica Appears Harmless but Can Instantly Kill Anyone at the Entrance

Anavex Life Sciences Alzheimer's Treatment Brings Hope to Millions

Space Weather Alert: NOAA Warns of a Solar Radiation Storm With 60% Chance of Hitting the Earth This Week

The AI Revolution in Investment Management

Solar Storm Alert: Rare Cosmic Event, First in 20 Years, Threatens Earth's Tech

Recommended Stories

Helium Leak Delays Boeing’s Astronaut Launch Attempt for the Second Time; Crew Debut Set on May 21 After Spacecraft Repair

Bizarre Planet 'WASP-193b' Found To Have the Density of Cotton Candy Despite Its Enormous Size, Making It Second-Least Dense Exoplanet Ever Discovered

US Space Force Orders $414M Advanced Missile Defense Satellites To Track Hypersonic Threats

SpaceX’s Starship Megarocket Prepares for Next Test Flight in 3–5 Weeks, Confirms Elon Musk